Full interview: CytoDyn looks to FDA to green light Phase 2 trials of leronlimab to treat colon cancer
CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech has filed a Phase 2 protocol with the Food and Drug Administration for a combination therapy of leronlimab and regorafenib to treat patients with metastatic colorectal cancer.
Dr Pourhassan explains that the Vancouver, Washington-based biotechnology company's animal studies with this indication show "strong results" so there is no reason why CytoDyn should not progress to Phase 2 trials.
Quick facts: CytoDyn
Market Cap: $162.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment...FOR OUR FULL DISCLAIMER CLICK HERE